The T cell receptor (TCR) complex is a naturally occurring antigen sensor that detects,
amplifies and coordinates cellular immune responses to epitopes derived from cell surface …

CRISPR offers new hope for many patients and promises to transform the way we think of
future therapies. Ensuring safety of CRISPR therapeutics is a top priority for clinical …

T cell receptors (TCRs) enable T cells to specifically recognize mutations in cancer cells,–.
Here we developed a clinical-grade approach based on CRISPR–Cas9 non-viral precision …

Neoantigens are peptides derived from non-synonymous mutations presented by human
leukocyte antigens (HLAs), which are recognized by antitumour T cells,,,,,,,,,,,,–. The large …

Radiotherapy is a mainstay of glioblastoma (GBM) treatment; however, the development of
therapeutic resistance has hampered the efficacy of radiotherapy, suggesting that additional …

Inefficient knock-in of transgene cargos limits the potential of cell-based medicines. In this
study, we used a CRISPR nuclease that targets a site within an exon of an essential gene …

Abstract Background Chimeric Antigen Receptor (CAR) T cells are now standard of care
(SOC) for some patients with B cell and plasma cell malignancies and could disrupt the …

Background Multiple genetic modifications may be required to develop potent off-the-shelf
chimeric antigen receptor (CAR) T cell therapies. Conventional CRISPR-Cas nucleases …

Chimeric antigen receptor (CAR) T-cell therapy has proven a breakthrough in cancer
treatment in the last decade, giving unprecedented results against hematological …

Adoptive T‐cell transfer (ACT) therapies, including of tumor infiltrating lymphocytes (TILs)
and T cells gene‐modified to express either a T cell receptor (TCR) or a chimeric antigen …